48 research outputs found

    Bone abnormalities in latent TGF-β binding protein (Ltbp)-3–null mice indicate a role for Ltbp-3 in modulating TGF-β bioavailability

    Get PDF
    The TGF-βs are multifunctional proteins whose activities are believed to be controlled by interaction with the latent TGF-β binding proteins (LTBPs). In spite of substantial effort, the precise in vivo significance of this interaction remains unknown. To examine the role of the Ltbp-3, we made an Ltbp-3–null mutation in the mouse by gene targeting. Homozygous mutant animals develop cranio-facial malformations by day 10. At 2 mo, there is a pronounced rounding of the cranial vault, extension of the mandible beyond the maxilla, and kyphosis. Histological examination of the skulls from null animals revealed ossification of the synchondroses within 2 wk of birth, in contrast to the wild-type synchondroses, which never ossify. Between 6 and 9 mo of age, mutant animals also develop osteosclerosis and osteoarthritis. The pathological changes of the Ltbp-3–null mice are consistent with perturbed TGF-β signaling in the skull and long bones. These observations give support to the notion that LTBP-3 is important for the control of TGF-β action. Moreover, the results provide the first in vivo indication for a role of LTBP in modulating TGF-β bioavailability

    Enamel and dental anomalies in latent-transforming growth factor beta-binding protein 3 mutant mice.

    Get PDF
    Latent-transforming growth factor beta-binding protein 3 (LTBP-3) is important for craniofacial morphogenesis and hard tissue mineralization, as it is essential for activation of transforming growth factor-β (TGF-β). To investigate the role of LTBP-3 in tooth formation we performed micro-computed tomography (micro-CT), histology, and scanning electron microscopy analyses of adult Ltbp3-/- mice. The Ltbp3-/- mutants presented with unique craniofacial malformations and reductions in enamel formation that began at the matrix formation stage. Organization of maturation-stage ameloblasts was severely disrupted. The lateral side of the incisor was affected most. Reduced enamel mineralization, modification of the enamel prism pattern, and enamel nodules were observed throughout the incisors, as revealed by scanning electron microscopy. Molar roots had internal irregular bulbous-like formations. The cementum thickness was reduced, and microscopic dentinal tubules showed minor nanostructural changes. Thus, LTBP-3 is required for ameloblast differentiation and for the formation of decussating enamel prisms, to prevent enamel nodule formation, and for proper root morphogenesis. Also, and consistent with the role of TGF-β signaling during mineralization, almost all craniofacial bone components were affected in Ltbp3-/- mice, especially those involving the upper jaw and snout. This mouse model demonstrates phenotypic overlap with Verloes Bourguignon syndrome, also caused by mutation of LTBP3, which is hallmarked by craniofacial anomalies and amelogenesis imperfecta phenotypes.journal article2017 Febimporte

    TGF-B and Breast Cancer Induction

    No full text

    TGF-Beta and Breast Cancer Induction

    No full text

    Latent TGF-β binding protein-3 (LTBP-3) requires binding to TGF-β for secretion

    Get PDF
    AbstractLatent transforming growth factor-β (TGF-β) binding protein (LTBP)-1, which is easily secreted, has been shown to enhance the secretion of TGF-β. Here we show that another member of the LTBP family, LTBP-3, is not secreted by several cell types, but secretion occurs after coexpression with TGF-β. The secretion of LTBP-3 requires complexing of LTBP-3 with Cys33 of the TGF-β propeptide

    Synthesis of 5-azaandrostane-3b,17b-diol protected at the 17b-hydroxyl group

    No full text
    In the present paper, the preparation of 3b-hydroxy-17b-dimethyl-tert-butylsilyloxy-5-azaandrostane (15) in fourteen steps is described. B-nor-17-oxoandrost-5-en-3b-yl acetate (1) was used as the starting material, which was transformed to the key intermediate of the synthesis, B-nor-17b-dimethyl-tert-butylsilyloxyandrost-4-en-3b-yl acetate (7)
    corecore